Predicting the Immune Response with NeoScreen®

Are you searching for Neo-Epitopes?

Our unique NeoScreen® Assay allows you to identify top neo-epitope candidates.

Tell me more!

SARS-CoV-2 Vaccine Efforts

Immunitrack is committed to playing a role in the fight against COVID-19 by applying our epitope immunogenicity prediction technology to support vaccine development.

Read more
What Immunitrack Does

Our aim is to help our customers predict the immune response. Immunogenicity prediction is a key need in the field of biologics, particularly for cancer vaccines. We want to help our customers to identify “real” epitopes (those that will cause a T-cell response) from pools of potential neo-epitopes generated by sequencing data.

Conversely (e.g., protein/peptide-based therapeutics), there is often a need to predict if an unwanted immune response can occur.

Watch video
Latest News
May 2, 2022

Immunitrack co-sponsors the PEGS Summit 2022

Read More
April 28, 2022

May 2022: Immunitrack presents at conferences in US, Europe and Japan

Read More
February 17, 2022

Immunitrack co-authors Molecular Therapy article that sheds new insights about AAV immunogenicity

Read More
November 17, 2021

Immunitrack welcomes Karin Absalonsen as new chairman of the board

Read More

Moving Biologics Discovery Forward

Immuno-oncology

Identify neo-epitopes faster.

Read more

Vaccines

Selecting immunogenic epitopes

Read more

TCR OFF-TARGET

De-risking candidate TCR and TCR-like therapies

Read more

DEIMMUNISATION

Predicting and minimising the immune response to candidate biologics

Read more

Immunitrack has a stellar reputation in the field of peptide-MHC manufacture. Communication was prompt and clear. Our MHC tetramers arrived within a short timeframe. This allowed us to do faster iterations on our project.

Immunologist Biotech Company, California

Novozymes Biopharma uses the FcRn from Immunitrack to develop the albumin based half-life extension platform Veltis®. We have tested a number of commercially available FcRn’s in our screening assay developed for identification of albumin variants with improved affinity for FcRn receptor and found that the biotinylated FcRn’s from Immunitrack deliver superior performance. These biotinylated FcRn’s enable a robust immobilization to Streptavidin-biosensors (Octet Red96 from Pall ForteBio) and deliver very consistent and robust data.

Birgitte Andersen Science manager, Novozymes